Allogene Therapeutics (ALLO) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 03/14/24
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdateGlobeNewsWire • 03/14/24
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune DiseaseGlobeNewsWire • 03/12/24
Allogene Therapeutics (ALLO)'s Technical Outlook is Bright After Key Golden CrossZacks Investment Research • 03/05/24
Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business UpdateGlobeNewsWire • 03/05/24
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care ConferenceGlobeNewsWire • 02/28/24
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in AsiaGlobeNewsWire • 02/16/24
Allogene Therapeutics to lay off over 20% of workforce amidst strategic shiftProactive Investors • 01/05/24
Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell LymphomaGlobeNewsWire • 01/04/24
Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell LymphomaGlobeNewsWire • 01/04/24
Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/24
Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of HematologyGlobeNewsWire • 12/09/23
Allogene Therapeutics Announces Participation in December Investor ConferenceGlobeNewsWire • 12/01/23
Allogene Therapeutics (ALLO) Upgraded to Strong Buy: Here's What You Should KnowZacks Investment Research • 11/10/23